{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:32:37Z","timestamp":1786527157502,"version":"build-2736575974"},"reference-count":20,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematol. Rep.","Hematology Reports"],"abstract":"<jats:p>Introduction: Autologous stem cell transplantation (ASCT) is regaining interest as a consolidation strategy for acute myeloid leukemia (AML) patients with favorable\/intermediate risk and measurable residual disease (MRD) negativity. In fit older adults, its role remains debated due to concerns regarding toxicity and stem cell collection. Aim: To evaluate the long-term outcomes of ASCT in AML patients aged \u226560 years in first complete remission (CR1). Methods: We retrospectively analyzed 43 non-M3 AML patients (median age 64, range 60\u201372) who underwent ASCT in CR1 across five centers (2000\u20132024). Risk was stratified by ELN 2017. Primary endpoints were overall survival (OS) and disease-free survival (DFS). Results: The cohort included 22 favorable-risk and 21 intermediate-risk patients. Most (88%) achieved CR1 after one induction course. Median neutrophil and platelet engraftment occurred at 13 and 15 days, respectively. Grade III\/IV infections were observed in 28% of patients; transplant-related mortality was low at 4%. At a median follow-up of 77 months, 5-year OS and DFS were 51% (95% CI: 37\u201370%) and 47% (95% CI: 34\u201365%), respectively. OS was significantly superior in favorable- versus intermediate-risk patients (68% vs. 35%, p = 0.027), with a similar trend for DFS (57% vs. 35%, p = 0.07). The number of consolidation cycles did not impact survival outcomes. Conclusions: This multicenter study confirms that ASCT is a feasible and effective consolidation strategy for selected fit AML patients aged \u226560. The low mortality and encouraging survival, particularly in favorable-risk subgroups, support ASCT as a valid alternative to prolonged chemotherapy or maintenance.<\/jats:p>","DOI":"10.3390\/hematolrep18040057","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:57:26Z","timestamp":1786521446000},"page":"57","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is There Still a Role for Autologous Stem Cell Transplantation in Older Adults with AML?"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3064-9332","authenticated-orcid":false,"given":"Saveria","family":"Capria","sequence":"first","affiliation":[{"name":"Department of Hematology, AOU Policlinico Umberto I\u2014Sapienza University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Minotti","sequence":"additional","affiliation":[{"name":"Department of Hematology, AOU Policlinico Umberto I\u2014Sapienza University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-6162","authenticated-orcid":false,"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Bisegna","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Carmosino","sequence":"additional","affiliation":[{"name":"Department of Hematology, AOU Policlinico Umberto I\u2014Sapienza University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-1587","authenticated-orcid":false,"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[{"name":"Ematologia e Trapianto, Dipartimento di Scienze Ematologiche e di Laboratorio, Fondazione Policlinico Universitario A. Gemelli IRCCS, Sezione di Ematologia, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7101-7423","authenticated-orcid":false,"given":"Luca","family":"Di Marino","sequence":"additional","affiliation":[{"name":"Ematologia e Trapianto, Dipartimento di Scienze Ematologiche e di Laboratorio, Fondazione Policlinico Universitario A. Gemelli IRCCS, Sezione di Ematologia, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7267-3281","authenticated-orcid":false,"given":"Giovanni","family":"Luzi","sequence":"additional","affiliation":[{"name":"UOC Ematologia e Trapianto di Cellule Staminali, San Camillo-Forlanini Hospital, 00152 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1448-8112","authenticated-orcid":false,"given":"Sabrina","family":"Mariani","sequence":"additional","affiliation":[{"name":"Hematology Unit, AOU Sant\u2019Andrea, Sapienza University, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Marsili","sequence":"additional","affiliation":[{"name":"GIMEMA Foundation, 00182 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0607-0243","authenticated-orcid":false,"given":"Leonardo","family":"Marabitti","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elettra","family":"Ortu La Barbera","sequence":"additional","affiliation":[{"name":"Department of Hematology, SM Goretti Hospital, University Polo Pontino, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Scollo","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Martelli","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Maria","family":"Trisolini","sequence":"additional","affiliation":[{"name":"Department of Hematology, AOU Policlinico Umberto I\u2014Sapienza University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1159\/000531628","article-title":"Acute Myeloid Leukemia Treatment in the Elderly: A Comprehensive Review of the Present and Future","volume":"146","author":"Choi","year":"2023","journal-title":"Acta Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2024013744","article-title":"Fitness assessment in acute myeloid leukemia: Recommendations from an expert panel on behalf of the European Leukemia","volume":"9","author":"Venditti","year":"2025","journal-title":"Net. Blood Adv."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e830","DOI":"10.1016\/S2352-3026(24)00241-2","article-title":"Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): Final report of a multicentre, single-arm, phase 2 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic Risk Classification for Adults with AML Receiving Less-Intensive Therapies: The 2024 ELN Recommendations","volume":"144","author":"Dinardo","year":"2024","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1200\/JCO.20.01392","article-title":"Accuracy of SIE\/SIES\/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm","volume":"38","author":"Palmieri","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Ferrara, F., and Picardi, A. (2019). Is There Still a Role for Autologous Stem Cell Transplantation for the Treatment of Acute Myeloid Leukemia?. Cancers, 12.","DOI":"10.3390\/cancers12010059"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1200\/JCO.2008.20.6490","article-title":"Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: The EORTC and GIMEMA groups study AML-10","volume":"27","author":"Mandelli","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: Final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1002\/cncr.23927","article-title":"Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival","volume":"113","author":"Borthakur","year":"2008","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.leu.2404149","article-title":"Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations","volume":"20","author":"Gorello","year":"2006","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.2025031480","article-title":"2025 update on MRD in acute myeloid leukemia: A consensus document from the ELN-DAVID MRD Working Party","volume":"147","author":"Cloos","year":"2026","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1182\/bloodadvances.2019001349","article-title":"Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results","volume":"4","author":"Gardin","year":"2020","journal-title":"Blood Adv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/bloodadvances.2025017934","article-title":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"10","author":"Sekeres","year":"2026","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1182\/blood-2011-07-370247","article-title":"Autologous peripheral blood stem cell transplantation for acute myeloid leukemia","volume":"118","author":"Vellenga","year":"2011","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJM199501263320403","article-title":"Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous Leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche MaligNe dell\u2019Adulto (GIMEMA) Leukemia Cooperative Groups","volume":"332","author":"Zittoun","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood.2018886960","article-title":"GIMEMA AML1310 Trial of Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia","volume":"134","author":"Venditti","year":"2019","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission","volume":"383","author":"Wei","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/4\/57\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:52:17Z","timestamp":1786524737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/4\/57"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["hematolrep18040057"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep18040057","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}